A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions

Trial Profile

A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions

Completed
Phase of Trial: Phase II

Latest Information Update: 25 May 2015

At a glance

  • Drugs L19 TNF fusion protein (Primary) ; L19-IL2 fusion protein (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 25 May 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record
    • 31 May 2014 The study design presented at 50th Annual Meeting of the American Society of Clinical Oncology.
    • 02 May 2014 New source identified and integrated (ClinicalTrial.gov; NCT02076633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top